CLAIMS

1. Use of a composition comprising an antagonist of a Programmed Death 1 protein (PD-1) and eribulin or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment of triple negative breast cancer in an individual.

2. The use of claim 1, wherein the individual is a human.

3. The use of claim 1 or 2, wherein the triple negative breast cancer is metastatic.

4. The use of any one of claims 1 to 3, wherein the PD-1 antagonist is pembrolizumab and the pharmaceutically acceptable salt of eribulin is eribulin mesylate.

5. A medicament comprising a combination of an antagonist of a Programmed Death 1 protein (PD-1) and eribulin or a combination of a Programmed Death 1 protein (PD-1) and a pharmaceutically acceptable salt of eribulin for use in treating triple negative breast cancer in an individual.

6. The medicament of claim 5, wherein the individual is a human.

7. The medicament of claim 5 or 6, wherein the triple negative breast cancer tests positive for PD-Ll expression by an immunohistochemical (IHC) assay.

8. The medicament of any one of claims 5 to 7, wherein the breast cancer is metastatic.

9. The medicament of any one of claims 5 to 8, wherein the PD-1 antagonist is pembrolizumab and the pharmaceutically acceptable salt of eribulin is eribulin mesylate.

10. The medicament of claim 9, wherein pembrolizumab is formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab, 7% (w/v) sucrose, 0.02% (w/v)

polysorbate 80 in 10 mM histidine buffer pH 5.5, and eribulin or a pharmaceutically acceptable salt thereof is formulated as a liquid medicament which comprises 0.5 mg/mL eribulin mesylate.

11. A kit comprising a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising an antagonist of a Programmed Death 1 protein (PD-1), the second container comprising at least one dose of a medicament comprising eribulin or a pharmaceutically acceptable salt thereof, and a package insert comprising instructions for treating an individual for triple negative breast cancer using the medicaments.

12. The kit of claim 11, wherein the instructions state that the medicaments are intended for use in treating an individual having a breast cancer that tests positive for PD-L1 expression by an immunohistochemical (IHC) assay.

13. The kit of claim 11 or 12, wherein the individual is a human.

14. The kit of any one of claims 11 to 13, wherein the PD-1 antagonist is pembrolizumab formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab, 7% (w/v) sucrose, 0.02% (w/v) polysorbate 80 in 10 mM histidine buffer pH 5.5 and the pharmaceutically acceptable salt of eribulin is eribulin mesylate formulated as a liquid medicament which comprises 0.5 mg/mL eribulin mesylate.

15. The kit of any one of claims 11 to 14, wherein the triple negative breast cancer is metastatic.

16. The use of claim 1, wherein the eribulin or the pharmaceutically acceptable salt thereof is to be administered at a dose of 1.4 mg/m^2, 1.1 mg/m^2, or 0.7 mg/m^2 on days 1 and 8 of a 21-day cycle and pembrolizumab is to be administered at a dose of 200 mg Q3W.

17. The medicament of claim 9, wherein the eribulin mesylate is to be administered to the individual at a dose of 1.4 mg/m^2, 1.1 mg/m^2, or 0.7 mg/m^2 on days 1 and 8 of a 21-day cycle and pembrolizumab is to be administered to the individual at a dose of 200 mg Q3W.